Avalo Therapeutics (AVTX) – Investment Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Avalo Therapeutics (NASDAQ: AVTX) in the last few weeks:

• 4/9/2026 – Avalo Therapeutics is now covered by Wolfe Research. They set an “outperform” rating and a $48.00 price target on the stock.
• 4/8/2026 – Avalo Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/8/2026 – Avalo Therapeutics is now covered by Wolfe Research. They set an “outperform” rating and a $48.00 price target on the stock.
• 4/6/2026 – Avalo Therapeutics is now covered by Citizens Jmp. They set an “outperform” rating and a $52.00 price target on the stock.
• 3/29/2026 – Avalo Therapeutics was upgraded by Wall Street Zen from “strong sell” to “hold”.
• 3/25/2026 – Avalo Therapeutics had its price target raised by HC Wainwright from $25.00 to $40.00. They now have a “buy” rating on the stock.
• 3/24/2026 – Avalo Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $40.00 price target on the stock.

Insider Transactions at Avalo Therapeutics

In related news, insider Mittie Doyle sold 3,970 shares of the business’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $18.01, for a total transaction of $71,499.70. Following the completion of the sale, the insider owned 3,622 shares of the company’s stock, valued at $65,232.22. This represents a 52.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christopher Ryan Sullivan sold 7,980 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $17.15, for a total transaction of $136,857.00. Following the sale, the chief financial officer directly owned 17,338 shares of the company’s stock, valued at approximately $297,346.70. This represents a 31.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 46,100 shares of company stock valued at $764,724. Insiders own 3.03% of the company’s stock.

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.